- Home
- CAPR vs FMAO Comparison
CAPR vs FMAO Comparison
Compare CAPR & FMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- FMAO
- Stock Information
- Founded
- CAPR 2005
- FMAO 1897
- Country
- CAPR United States
- FMAO United States
- Employees
- CAPR N/A
- FMAO N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- FMAO Savings Institutions
- Sector
- CAPR Health Care
- FMAO Finance
- Exchange
- CAPR Nasdaq
- FMAO Nasdaq
- Market Cap
- CAPR 324.6M
- FMAO 337.2M
- IPO Year
- CAPR N/A
- FMAO N/A
- Fundamental
- Price
- CAPR $6.92
- FMAO $23.01
- Analyst Decision
- CAPR Strong Buy
- FMAO
- Analyst Count
- CAPR 6
- FMAO 0
- Target Price
- CAPR $23.00
- FMAO N/A
- AVG Volume (30 Days)
- CAPR 1.1M
- FMAO 20.0K
- Earning Date
- CAPR 11-11-2025
- FMAO 10-27-2025
- Dividend Yield
- CAPR N/A
- FMAO 3.96%
- EPS Growth
- CAPR N/A
- FMAO 38.20
- EPS
- CAPR N/A
- FMAO 2.33
- Revenue
- CAPR $13,392,150.00
- FMAO $114,071,000.00
- Revenue This Year
- CAPR N/A
- FMAO $3.38
- Revenue Next Year
- CAPR $7,894.07
- FMAO $6.39
- P/E Ratio
- CAPR N/A
- FMAO $9.86
- Revenue Growth
- CAPR N/A
- FMAO 16.39
- 52 Week Low
- CAPR $5.68
- FMAO $20.88
- 52 Week High
- CAPR $22.90
- FMAO $34.15
- Technical
- Relative Strength Index (RSI)
- CAPR 53.74
- FMAO 37.91
- Support Level
- CAPR $6.05
- FMAO $23.83
- Resistance Level
- CAPR $6.42
- FMAO $24.99
- Average True Range (ATR)
- CAPR 0.39
- FMAO 0.94
- MACD
- CAPR -0.01
- FMAO -0.06
- Stochastic Oscillator
- CAPR 56.28
- FMAO 5.31
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.